Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report

Table 1 The binding scores of individual peptides for the patient’s HLA class I and II haplotypes and CD1d

Peptide	Protien origin	Peptide sequence	MHC class I	Net MHC [32, 33]	Syfpeithi [34]	CD1d	Castano [55]	MHC class II	Net MHC II pan3.1 [35]
1	RIM1	WEAKPSRIL	B*18	WB	+(17)	CD1d	−	DRB1*1101	NB
			B*44	WB		CD1d	−	DRB1*1301	NB
		(WEAKPSRI)	B*44	SB	+(21)	–	−
2	KIF4B	GIAARVKNWL	A*02	NB	+(22)	CD1d	+	DRB1*1101	WB
								DRB1*1301	WB
3	KIF4B	KEGIAARVKNW	B*44	WB	−(14)	CD1d	+	DRB1*1101	NB
								DRB1*1301	NB
		(EGIAARVKNW)	B*44	SB	−(14)	CD1d	+
4	RIM1	EAKPSRILM	A*02	NB	−(6)	CD1d	−	DRB1*1101	NB
								DRB1*1301	NB

The binding scores of individual peptides for the patient’s HLA haplotypes were determined via NetMHC [32, 33], SYFPEITHI [34], CD1d-binding algorithm according to “Castano” (1-4-7 rule) [55] and NetMHCIIpan version 3.1 [35]
Then likelihood for presentation is given as “+” and “−” respectively; SYFPEITHI half max scores regarding MHC class I presentation are given in brackets. Mutations in the peptides are indicated by underline
WB weak binder, SB strong binder, NB no binding predicted

ISSN: 1479-5876